36 min listen
Looking Ahead in Complement-Mediated Kidney Diseases: What Clinical Questions Do Current Trials Aim to Answer
Looking Ahead in Complement-Mediated Kidney Diseases: What Clinical Questions Do Current Trials Aim to Answer
ratings:
Length:
34 minutes
Released:
May 30, 2023
Format:
Podcast episode
Description
Did you know that, if left untreated, between 30% and 50% and up to 30% of patients with C3G and IgAN, respectively, will progress to end-stage kidney disease in 10 years? Credit available for this activity expires: 5/30/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/992405?ecd=bdc_podcast_libsyn_mscpedu
Released:
May 30, 2023
Format:
Podcast episode
Titles in the series (100)
Acute Myeloid Leukemia Beyond FLT3 and IDH: The Role of Non-Targetable Driver Mutations: Do you understand the role of non-targetable driver mutations in the management of acute myeloid leukemia (AML)? Credit available for this activity expires: 5/1/2024 Earn Credit / Learning Objectives & Disclosures: by Keeping Current CME